← back to search

Jing‐Quan Wang

Jiangsu University · CN
Area of research
Oncology · Molecular Biology
Research interest
Research focused on Multiple drug resistance and Pharmacology, with related work in Abcg2, ATP-binding cassette transporter, ABCC1. Notable publications include 'Gold nanoparticles: synthesis, physiochemical properties and therapeutic applications in cancer', 'Paclitaxel resistance related to nuclear envelope structural sturdiness', and 'Tetrandrine Interaction with ABCB1 Reverses Multidrug Resistance in Cancer Cells Through Competition with Anti-Cancer Drugs Followed by Downregulation of ABCB1 Expression'.
h-index
citations
560
works
13
NIH funding
primary concept
email

Recent publications

Innovative and environmentally friendly MICP surface curing: Enhancing mechanical and durability properties of concrete
Journal of Cleaner Production 2024cited by 39position: middledoi
ABCB1-dependent collateral sensitivity of multidrug-resistant colorectal cancer cells to the survivin inhibitor MX106-4C
Drug Resistance Updates 2024cited by 27position: middledoi
Overexpression of ABCC1 and ABCG2 confers resistance to talazoparib, a poly (ADP-Ribose) polymerase inhibitor
Drug Resistance Updates 2023cited by 28position: middledoi
Paclitaxel resistance related to nuclear envelope structural sturdiness
Drug Resistance Updates 2022cited by 81position: middledoi
Gold nanoparticles: synthesis, physiochemical properties and therapeutic applications in cancer
Drug Discovery Today 2021cited by 121position: middledoi
Overexpression of ABCC1 Confers Drug Resistance to Betulin
Frontiers in Oncology 2021cited by 34position: middledoi
Overexpression of ABCG2 Confers Resistance to MLN7243, a Ubiquitin-Activating Enzyme (UAE) Inhibitor
Frontiers in Cell and Developmental Biology 2021cited by 26position: middledoi
Natural Product as Substrates of ABC Transporters: A Review
Recent Patents on Anti-Cancer Drug Discovery 2021cited by 17position: middledoi
Contributors
Elsevier eBooks 2021cited by 0position: middledoi
Venetoclax, a BCL-2 Inhibitor, Enhances the Efficacy of Chemotherapeutic Agents in Wild-Type ABCG2-Overexpression-Mediated MDR Cancer Cells
Cancers 2020cited by 52position: firstdoi
Erdafitinib Antagonizes ABCB1-Mediated Multidrug Resistance in Cancer Cells
Frontiers in Oncology 2020cited by 49position: middledoi
NVP-CGM097, an HDM2 Inhibitor, Antagonizes ATP-Binding Cassette Subfamily B Member 1-Mediated Drug Resistance
Frontiers in Oncology 2020cited by 22position: middledoi
Tetrandrine Interaction with ABCB1 Reverses Multidrug Resistance in Cancer Cells Through Competition with Anti-Cancer Drugs Followed by Downregulation of ABCB1 Expression
Molecules 2019cited by 64position: middledoi
Derivative of 5-cyano-6-phenylpyrimidin antagonizes ABCB1- and ABCG2-mediated multidrug resistance
European Journal of Pharmacology 2019cited by 29position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Zhe‐Sheng Chen · St. John's University10 papers (2019–2024) · 6 papers (2019–2023)Zi‐Ning Lei · St. John's University6 papers (2019–2024)Yuqi Yang · National University of Singapore5 papers (2020–2023)Xuan-Yu Chen · National Chung Hsing University4 papers (2020–2021)Dong‐Hua Yang · The Ohio State University4 papers (2019–2022) · 4 papers (2020–2023)Yihang Pan · Sun Yat-sen University3 papers (2020–2024)Qingbin Cui · St. John's University3 papers (2020–2020)Leli Zeng · Sun Yat-sen University3 papers (2020–2021)Jing Li · China Pharmaceutical University3 papers (2020–2021) · 2 papers (2023–2024)Chao‐Yun Cai · St. John's University2 papers (2019–2019)Weiguo Feng · St. John's University2 papers (2020–2020)Ning Ji · Chinese Academy of Medical Sciences & Peking Union Medical College2 papers (2019–2020)Xing-Duo Dong · Union Hospital2 papers (2020–2020) · 2 papers (2019–2020)Guiyu Zhang · Guangzhou University of Chinese Medicine1 papers (2024–2024)Pranav Gupta · Children's Healthcare of Atlanta1 papers (2019–2019)Elizabeth R. Smith · University of Miami1 papers (2022–2022)